A retrospective study on the incidence, management and risk factors of skin rash in patients with advanced prostate cancer in Japan

[1]  N. Hinata,et al.  Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium , 2022, International Journal of Clinical Oncology.

[2]  Youqing Wang,et al.  Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019 , 2022, Frontiers in Public Health.

[3]  A. Armstrong,et al.  Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study , 2021, International journal of urology : official journal of the Japanese Urological Association.

[4]  V. Sundaram,et al.  Survival analysis—part 2: Cox proportional hazards model , 2021, Indian Journal of Thoracic and Cardiovascular Surgery.

[5]  M. Poncet,et al.  Prevalence of Pruritus in the Elderly with Dementia: A Multicenter Survey of Japanese Patients , 2020, Acta dermato-venereologica.

[6]  H. Uemura,et al.  Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study , 2020, BMC Urology.

[7]  G. S. Walker,et al.  Enzalutamide and Apalutamide: In vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model. , 2019, Chemical research in toxicology.

[8]  A. Hussain,et al.  Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy , 2019, Journal of medical economics.

[9]  Tanya Stoyanova,et al.  Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer , 2019, Front. Oncol..

[10]  N. Agarwal,et al.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[13]  M. Tohkin,et al.  Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors , 2018, International journal of medical sciences.

[14]  H. Hunger,et al.  EDITION , 2018, Moshe Bar Kepha's Commentary on the Gospel of Luke.

[15]  J. D. de Bono,et al.  Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise. , 2018, Cold Spring Harbor perspectives in medicine.

[16]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[17]  T. Saika,et al.  Role of robot‐assisted radical prostatectomy in locally advanced prostate cancer , 2018, International journal of urology : official journal of the Japanese Urological Association.

[18]  Y. Kakehi,et al.  Evidenced‐based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition) , 2017, International journal of urology : official journal of the Japanese Urological Association.

[19]  P. Demoly,et al.  Supporting the validation of the new allergic and hypersensitivity conditions section of the World Health Organization International Classification of Diseases-11 , 2016, Asia Pacific allergy.

[20]  R. Hay,et al.  Age-Associated Skin Conditions and Diseases: Current Perspectives and Future Options. , 2016, The Gerontologist.

[21]  S. Kurtin,et al.  Practical Management of Lenalidomide-Related Rash. , 2015, Clinical lymphoma, myeloma & leukemia.

[22]  A. D'Amico,et al.  Adverse effects of androgen deprivation therapy and strategies to mitigate them. , 2015, European urology.

[23]  Katherine E Henson,et al.  Risk of Suicide After Cancer Diagnosis in England , 2018, JAMA psychiatry.

[24]  Kazuto Ito.  Prostate cancer in Asian men , 2014, Nature Reviews Urology.

[25]  H. Sanada,et al.  Prevalence of asteatosis and asteatotic eczema among elderly residents in facilities covered by long‐term care insurance , 2013, The Journal of dermatology.

[26]  A. Partin,et al.  Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  O. Ogawa,et al.  Age‐associated increase of prostate‐specific antigen in a high level of men visiting urological clinics , 2005, International journal of urology : official journal of the Japanese Urological Association.

[28]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[29]  Nigel Borley,et al.  Prostate cancer: diagnosis and staging. , 2009, Asian journal of andrology.

[30]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[31]  K. Jenpanich,et al.  [Drug administration]. , 1976, Thai journal of nursing.